CHINA FDA approves drug made by China's BeiGene to treat rare form of lymphoma

CHINA

FDA approves drug made by China's BeiGene to treat rare form of lymphoma

CGTN

09:20, November 15, 2019

5d7f181fc4af4a4ab07b2da1227f9c96-2.png

File photo: CGTN

The U.S. Food and Drug Administration (FDA) Thursday approved BeiGene Ltd's zanubrutinib (Brukinsa) capsules for the treatment of mantle cell lymphoma (MCL) in adults who have received at least one prior therapy.

BeiGene, a Chinese biotechnology company, tested Brukinsa in 118 MCL patients in two studies. According to BeiGene, 75 percent of the patients studied were Asian, 21 percent Caucasian, and 10-15 percent American.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue